{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:39:45Z","timestamp":1768207185351,"version":"3.49.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>To compare hexaminolevulinate (HAL) blue light cystoscopy (BLC) with white light cystoscopy (WLC) in the detection of bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients received intravesical HAL (Hexvix\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) and underwent WLC before randomization to undergo high-definition BLC (System blue). Lesions identified in either WLC or BLC were evaluated by a blinded panel. The primary efficacy endpoint was the proportion of patients with histology-confirmed tumors (Ta, T1, or CIS) and with at least one such tumor found by BLC but not by WLC. The secondary endpoints included the detection of CIS, lesion detection rates, false-positive rate, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 158 (160 screened patients) enrolled patients, 120 underwent WLC and were randomized (6 WLC, 114 BLC), and 97 were diagnosed with NMIBC. The mean age was 65.30 \u00b1 12.18 years. Out of the 114 patients, 13 (11.4%) suffered from CIS; 84.6% (11\/13) were detected with additional lesions by BLC; and 61.5% (8\/13) were diagnosed solely by BLC. Compared with WLC, the proportion of patients with additional bladder cancer lesions detected by HAL BLC was 43.3% [(33.27%, 53.75%),\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001]. The proportion of patients with CIS lesions detected by HAL BLC and not by WLC was 9.6% (4.9%, 16.6%). The detection rates for CIS, Ta, T1, and T2\u2013T4 tumors were 94.7%, 100%, 98.2%, and 100% for BLC and 42.1%, 76.1%, 91.2%, and 100% for WLC, respectively. The false-positive rates were 23.2% (19.2%, 27.7%) and 16.0% (11.9%, 20.8%) for BLC and WLC, respectively. A total of 95 patients (60.1%) reported 200 cases of AE, with 9 AEs being drug-related (fever, bladder pain, etc.). Nine device deficiencies (5.7%) occurred (eight quality issues and one device failure). No AEs and SAEs led to discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the setting of modern high-definition equipment, HAL BLC significantly improves the detection of bladder cancer with favorable safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2025.1713128","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:29Z","timestamp":1768196369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China"],"prefix":"10.3389","volume":"5","author":[{"given":"Hailong","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonglian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Haefner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd-Claus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Young-Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","volume-title":"Global cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"B5","unstructured":"<NCCN guidelines Version 3.2023 Bladder Cancer[EB\/OL].pdf>"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.04.013","article-title":"Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/srep10905","article-title":"A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study","volume":"5","author":"Ye","year":"2015","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B9","year":"2020"},{"key":"B10","unstructured":"National Health Commission of the People\u2019s Republic of China\n          \n          \n          2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.034","article-title":"A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer","volume":"178","author":"Grossman","year":"2007","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/end.2008.0574","article-title":"Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors","volume":"23","author":"Geavlete","year":"2009","journal-title":"J Endourol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000100480.70769.0e","article-title":"Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy","volume":"171","author":"Schmidbauer","year":"2004","journal-title":"J Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and Safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: A phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215603274","article-title":"Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder","volume":"7","author":"Di Stasi","year":"2015","journal-title":"Ther Adv Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study","volume":"174","author":"Jocham","year":"2005","journal-title":"J Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/end.2021.0313","article-title":"Blue light versus white light transurethral resection of bladder tumors: results from a contemporary series","volume":"35","author":"Morelli","year":"2021","journal-title":"J Endourol"},{"key":"B20","article-title":"Meta-analysis of photodynamic diagnosis in bladder cancer: oncologic and recurrence outcomes","volume":"39","author":"Maisch","year":"2021","journal-title":"World J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16364","article-title":"Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis","volume":"134","author":"Sari Motlagh","year":"2024","journal-title":"BJU Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102248","DOI":"10.1016\/j.pdpdt.2021.102248","article-title":"Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"34","author":"Sun","year":"2021","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03866-4","article-title":"Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results","volume":"40","author":"de la Rosette","year":"2022","journal-title":"World J Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15723","article-title":"Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review","volume":"130","author":"Maisch","year":"2022","journal-title":"BJU Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1097\/01.JU.0001008712.53259.7d.05","article-title":"PD48-05\u2003use of blue light cystoscopy among non-muscle invasive bladder cancer patients and outcomes in an equal access setting: a propensity scored matched analysis","volume":"211","author":"Das","year":"2024","journal-title":"J Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10374.x","article-title":"Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)","volume":"109","author":"Geavlete","year":"2012","journal-title":"BJU Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10090.x","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study","volume":"108","author":"Hermann","year":"2011","journal-title":"BJU Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1255632","article-title":"Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.09.009","article-title":"Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder","volume":"30","author":"Lerner","year":"2012","journal-title":"Urol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060782.52358.04","article-title":"Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study","volume":"170","author":"Jichlinski","year":"2003","journal-title":"J Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.05.002","article-title":"Hexvix plus chemo","volume":"4","author":"Burger","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1925-0","article-title":"Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III","volume":"35","author":"Bach","year":"2017","journal-title":"World J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071268","article-title":"Racial differences in the detection rate of bladder cancer using blue light cystoscopy: insights from a multicenter registry","volume":"16","author":"Ladi-Seyedian","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0068-x","article-title":"Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer","volume":"18","author":"Yang","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.03.006","article-title":"Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data","volume":"84","author":"Witjes","year":"2014","journal-title":"Urology"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2025.1713128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:31Z","timestamp":1768196371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2025.1713128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":35,"alternative-id":["10.3389\/fruro.2025.1713128"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2025.1713128","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1713128"}}